
AIDP Hires Ingredients Distributor for Australia, New Zealand
Pathway is currently pursuing TGA approval for AIDP ingredients Magtein, KoACT, and enVantec.
Pathway is currently pursuing approval for all three ingredients from the Australia’s Therapeutic Goods Administration, AIDP said. “We’re on the doorstep of TGA approval for Magtein and enVantec and convinced these branded products will be well received in Australia and New Zealand,” said Kathy Lund, AIDP’s director of business development, in a press release.
“Pathway is positioned to undertake the required regulatory work for these ingredients and has a proven track record in this process. While we’re waiting for TGA approval, we have time to work with our customers in parallel with this process. Furthermore, future market launches will be planned to coincide with the final TGA approval,” added Wayne Coote, managing director for Pathway International Pty Ltd.
Lund continued, “Furthermore, while we can’t place a dollar amount on this expansion, according to a recent article in Australia’s Daily Telegraph, despite the impact of ongoing global uncertainty and uneven conditions across sectors, the International Monetary Fund expects the Australian economy will outpace all major advanced economies over the next two years, and forecasts growth of 3.0% in 2012 and 3.5% in 2013. So we think this is a good place for brand expansion.”
Newsletter
From ingredient science to consumer trends, get the intel you need to stay competitive in the nutrition space—subscribe now to Nutritional Outlook.





